Research article
Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ
-
* Corresponding author: E Shelley Hwang shelley.hwang@ucsfmedctr.org
1 Department of Pathology, University of California San Francisco, San Francisco, USA
2 Department of Laboratory Medicine, University of California San Francisco, San Francisco, USA
3 Department of Surgery, University of California San Francisco, San Francisco, USA
4 Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, USA
5 Department of Surgery, Kaiser Permanente, Oakland, USA
BMC Cancer 2009, 9:285 doi:10.1186/1471-2407-9-285
Published: 18 August 2009Additional files
Additional file 1:
Clinical parameters of study population. Clinical characteristics of study population.
Format: DOC Size: 76KB Download file
This file can be viewed with: Microsoft Word Viewer
Additional file 2:
Immunohistochemistry. Comparison of pathologic features between pre- and post-treatment specimens.
Format: DOC Size: 141KB Download file
This file can be viewed with: Microsoft Word Viewer
Additional file 3:
Representative low-power figures of ER, Ki67, CD68, and caspase 3 staining in low, intermediate, and high grade DCIS. All cases shown are post-treatment specimens. (A) ER strong staining (90%) in low grade DCIS. (B) ER weak staining (25%) in intermediate grade DCIS. (C) Ki67 strong staining (26%) in high grade DCIS. (D) Ki67 weak staining (7%) in intermediate grade DCIS. (E) CD68 strong staining (score 164) in intermediate grade DCIS. (F) CD68 weak staining (score 96) in intermediate grade DCIS. (G) caspase 3 strong staining (8.8%) in high grade DCIS. (H) caspase 3 weak staining (1.6%) in intermediate grade DCIS.
Format: DOC Size: 13.4MB Download file
This file can be viewed with: Microsoft Word Viewer